Yaoyou Pharmaceuticals, a subsidiary of Heavy Pharmaceutical Holdings (000950.SZ), signed a licensing agreement with Pfizer

Zhitong Financial App News, China Pharmaceutical Holdings (000950.SZ) announced that Chongqing Pharmaceutical (Group) Co., Ltd., a holding subsidiary of the company, holds 38.67% of the shares in Chongqing Yaoyou Pharmaceutical Co., Ltd. (“Pharmacou Pharmaceutical” for short). Yaoyou Pharmaceutical has granted Pfizer exclusive development, production, and use of oral small molecule glucagon-like peptide-1 receptor (including YP05002) agonists (including YP05002) and products containing this active ingredient in the licensed region (i.e. worldwide) and field (i.e. treatment, diagnosis and prevention of all indications in humans and animals) GLP-1R Commercialization rights; With respect to this license, Yaoyou Pharmaceutical will be entitled to receive (including) a non-refundable down payment of 150 million US dollars and development milestone payments of up to 350 million US dollars based on clinical and commercialization progress of the licensed product.

According to the announcement, YP05002 is an oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist independently developed by Yaoyou Pharmaceutical and has independent intellectual property rights; it mainly promotes pancreatic insulin secretion and reduces glucagon secretion by activating human GLP-1R, inhibits gastric emptying and intestinal peristalsis in the gastrointestinal tract, and reduces energy intake by influencing appetite. It is used to treat type 2 diabetes, obesity, and related diseases. YP05002 is intended for the treatment of diseases related to the metabolic field. Potential indications include, but are not limited to, long-term weight management, type 2 diabetes, and steatohepatitis associated with metabolic dysfunction (i.e. non-alcoholic steatohepatitis).